As the biotechnology industry matures, it has become possible to outsource nearly every aspect of a biotechnology company to an increasingly capable service sector. Many start-ups can significantly increase their value with very lean staffs. This panel will discuss the strategic decisions that virtual biotech companies make to add value and mitigate risks.

Objective1: Prepare for the main risks and challenges presented by emerging markets.

Objective2: Understand actionable best practices and insights to help build organizational capabilities and improve deal processes.

Objective3: Learn from other industries what contributes to success and failure in emerging markets transactions.